Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer
Open Access
- 12 August 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (8) , e009587-13
Abstract
Background It is encountering the dilemma of lacking precise biomarkers to predict the response to neoadjuvant chemoimmunotherapy (NACI) and determine whether patients should use immune checkpoint inhibitors (ICIs) in early breast cancer (BC). We aimed to develop a gene signature to predict NACI response for BC patients and identify individuals suitable for adding ICIs. Patients and methods Two I-SPY2 cohorts and one West China Hospital cohort of patients treated with NACI were included. Machine learning algorithms were used to identify key genes. Principal component analysis was used to calculate the ImPredict (IP) score. The interaction effects between biomarkers and treatment regimens were examined based on the logistic regression analysis. The relationship between the IP score and immune microenvironment was investigated through immunohistochemistry (IHC) and multiplex IHC. Results The area under the curves of the IP score were 0.935, 0.865, and 0.841 in the discovery cohort, validation cohort 1, and in-house cohort. Marker-treatment interaction tests indicated that the benefits from immunotherapy significantly varied between patients with high and low IP scores (p for interaction Conclusions Our IP model shows favorable performance in predicting NACI response and is an effective tool for identifying BC patients who will benefit from ICIs. It may help clinicians optimize treatment strategies and guide clinical decision-making.Keywords
Funding Information
- the 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD18012)
- Post-Doctor Research Project, West China Hospital, Sichuan University (2021HXBH080)
- Natural Science Foundation of Sichuan Province (2022NSFSC1385)
This publication has 39 references indexed in Scilit:
- LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancerAnnals of Oncology, 2023
- LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)Annals of Oncology, 2023
- Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsJAMA Oncology, 2022
- The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunitiesCellular Oncology, 2021
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisAnnals of Oncology, 2021
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialCancer Cell, 2021
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer typesAnnals of Oncology, 2021
- The Challenges of Tumor Mutational Burden as an Immunotherapy BiomarkerCancer Cell, 2020
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment StrategiesCancer Cell, 2019